Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication June 7, 2018
- Accepted for publication July 21, 2018
- Published online March 1, 2019.
Article Versions
- previous version (August 2, 2018 - 13:54).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2019 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.
Author Information
- Frederik L. Giesel*,1,
- Clemens Kratochwil*,1,
- Thomas Lindner1,
- Manfred M. Marschalek1,
- Anastasia Loktev1,
- Wencke Lehnert2,
- Jürgen Debus3,4,
- Dirk Jäger5,
- Paul Flechsig1,
- Annette Altmann1,
- Walter Mier1 and
- Uwe Haberkorn1,6,7
- 1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg Germany
- 2ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft m.b.H, Dresden, Germany
- 3Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
- 4Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany
- 5Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany
- 6Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany; and
- 7Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany
- For correspondence or reprints contact: Uwe Haberkorn, Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. E-mail: uwe.haberkorn{at}med.uni-heidelberg.de
↵* Contributed equally to this work.
Cited By...
Article usage
68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers
Jump to section
Related Articles
Cited By...
- Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy
- Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-Labeled FAP Inhibitor
- Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging
- Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy
- The Role of 68Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience
- The Future of Nuclear Medicine Depends on the Quality of Its Research: Researchers at the University of Heidelberg Receive the Award for Best Article of the Year
- Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
- Reversibility of 68Ga-FAPI-2 Trapping Might Prove an Asset for PET Quantitative Imaging
- Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models
- FAP: The Next Billion Dollar Nuclear Theranostics Target?
- A Conversation Between Uwe Haberkorn and Johannes Czernin
- Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention
- Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
- The Future of Nuclear Medicine as an Independent Specialty
- Photoacoustic imaging as a tool to probe the tumour microenvironment
- 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer